Results 71 to 80 of about 95,020 (310)

DISSEMINATED OVARIAN CANCER: MODERN APPROACH TO DRUG THERAPY (REVIEW OF PUBLISHED LITERATURE)

Сибирский онкологический журнал, 2016
The review presents data on drug therapy for ovarian cancer including neoadjuvant and intraperitoneal chemotherapy. The prospects of using targeted therapy for ovarian cancer are discussed.
S. V. Molchanov, L. A. Kolomiets
doaj  

Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. [PDF]

, 2018
Synovial sarcoma (SS) is a recalcitrant subgroup of soft tissue sarcoma (STS). A tumor from a patient with high grade SS from a lower extremity was grown orthotopically in the right biceps femoris muscle of nude mice to establish a patient-derived ...
Dry, Sarah M, Eckardt, Mark A, Eilber, Fritz C, Gainor, Emily, Han, Qinghong, Hayashi, Katsuhiro, Higuchi, Takashi, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kimura, Hiroaki, Kiyuna, Tasuku, Li, Shukuan, Li, Yunfeng, Miwa, Shinji, Miyake, Kentaro, Miyake, Masuyo, Nelson, Scott D, Oshiro, Hiromichi, Russell, Tara A, Singh, Arun S, Tan, Yuying, Tsuchiya, Hiroyuki, Yamamoto, Norio   +23 more
core   +2 more sources

Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy

Advanced Materials, EarlyView.
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa, Gracia Mendoza, Silvia Irusta, Manuel Arruebo   +3 more
wiley   +1 more source

Executive Summary of the American Radium Society Appropriate Use Criteria for the Management of Peritoneal Carcinomatosis From Different Tumor Origins: Systematic Review and Guidelines

Cancer Medicine
Background Multimodality therapy incorporating a combination of cytoreductive surgery (CRS), intraperitoneal (IP) and systemic therapy continues to evolve for peritoneal carcinomatosis (PC) However, treatment and outcomes vary depending on tumor of ...
Expert Panel Management of Peritoneal Carcinomatosis, Timothy Kennedy, Sareena Singh, Gerard Abood, Eric Christenson, Christopher J. Anker, Dmitriy Akselrod, Christopher L. Hallemeier, Krishan R. Jethwa, Ed Kim, Percy Lee, Eric D. Miller, Neil B. Newman, J. Eva Selfridge, Navesh Sharma, William Small Jr, Leila Tchelebi, Vonetta M. Williams, Suzanne Russo   +18 more
doaj   +1 more source

Gastric and gastroesophageal junction cancer: Risk factors and prophylactic treatments for prevention of peritoneal recurrence after curative intent surgery

Annals of Gastroenterological Surgery, 2022
Aim Relapse after curative treatment for advanced gastric cancer, and especially peritoneal recurrence, is very common and has a dismal prognosis. The aim of this review is to summarize existing evidence regarding risk factors and prophylactic treatments
Biying Huang, Ioannis Rouvelas, Magnus Nilsson   +2 more
doaj   +1 more source

Multimodal Actuation and Environment Adaptive Strategies of Bio‐Inspired Micro/Nanorobots in Precision Medicine

Advanced Robotics Research, EarlyView.
An introduction for multidrive and environment‐adaptive micro/nanorobotics: design and fabrication strategies, intelligent actuation, and their applications. Various intelligent actuation approaches—magnetic, acoustic, optical, chemical, and biological—can be synergistically designed to enhance flexibility and adaptive behavior for precision medicine ...
Aiqing Ma, Han Gong, Jiacheng Ouyang, Liqi Chen, Tianfang Kang, Yiran He, Guojun Huang, Sidi Zheng, Ting Yin, Hong Pan, Lintao Cai   +10 more
wiley   +1 more source

Anesthetic implications in hyperthermic intraperitoneal chemotherapy

Journal of Anaesthesiology Clinical Pharmacology, 2019
Patients with peritoneal carcinomatosis were considered incurable with dismal survival rates till hyperthermic intraperitoneal chemotherapy after optimal cytoreductive surgery evolved. Perioperative management for these procedures is complex and involves
Nishkarsh Gupta, Vinod Kumar, Rakesh Garg, Sachidanand Jee Bharti, Seema Mishra, Sushma Bhatnagar   +5 more
doaj   +1 more source

Ovarialkarzinom: Chemotherapie intraperitoneal? [PDF]

Im Focus Onkologie, 2015
Die intraperitoneale Applikation der Chemotherapie bei fortgeschrittenem Ovarialkarzinom wird nicht routinemasig eingesetzt. Anhand gepoolter Daten der GOG (Gynecologic Oncology Group) wurde der Langzeiterfolg uberpruft.
openaire   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. [PDF]

, 2017
Malignant mesothelioma is a rare cancer that arises from the mesothelial cells that line the pleural cavity and less commonly from the peritoneal lining of the abdomen and pelvis.
Bastian, Boris C, Chen, Yunn-Yi, Garg, Karuna, Joseph, Nancy M, Nasr, Anthony, Onodera, Courtney, Rabban, Joseph T, Solomon, David A, Talevich, Eric, Yeh, Iwei, Zaloudek, Charles   +10 more
core   +2 more sources